MacroGenics sells manufacturing operations to Bora for $122.5M; West Pharma reports cybersecurity breach
MacroGenics announced it is selling its clinical and commercial drug substance manufacturing portfolio to CDMO Bora. The deal includes an upfront payment of $122.5 million.
The transaction transfers MacroGenics' manufacturing capabilities, covering both clinical trial material and commercial drug substance production, to Bora as part of its expansion in contract manufacturing.
In a separate report, West Pharma disclosed that it experienced a cybersecurity attack, which it said could affect its internal systems and data security.
The news also noted that Bavarian Nordic and OrganaBio have launched a new CDMO subsidiary, highlighting continued activity in the contract manufacturing sector.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “MacroGenics sells manufacturing arm; West Pharma discloses cybersecurity attack”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that